期刊
EMERGING INFECTIOUS DISEASES
卷 28, 期 1, 页码 127-138出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2801.210734
关键词
-
资金
- European Centre for Disease Prevention and Control
- European Commission Horizon 2020
We evaluated the incidence of invasive pneumococcal disease (IPD) in Europe during the 8 years of infant pneumococcal conjugate vaccine (PCV) programs using PCV10 and PCV13 vaccines. IPD incidence declined between 2011 and 2014, but increased between 2015 and 2018. The incidence of non-PCV13 serotypes increased while PCV13 serotypes decreased. Similar trends were observed in countries using PCV13 or PCV10 vaccines. The study highlights the need for new vaccines providing broader serotype protection.
We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >= 65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15-valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据